-
Breaking sex biases: access for all in haemophilia care Lancet Haematol. (IF 15.4) Pub Date : 2025-04-16 The Lancet Haematology
-
-
Sequential CAR T-cell therapy in myeloma: going from BCMA to GPRC5D Lancet Haematol. (IF 15.4) Pub Date : 2025-04-12 Niels W C J van de Donk, Carlos Fernandez de Larrea
-
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial Lancet Haematol. (IF 15.4) Pub Date : 2025-04-12 Jieyun Xia MD, Qian Sun MD, Dian Zhou MD, Hujun Li MD, Ying Wang MD, Yuekun Qi MD, Jiang Cao MD, Zhiling Yan MD, Depeng Li MD, Hai Cheng MD, Wei Sang MD, Feng Zhu MD, Haiying Sun MD, Wei Chen MD, Kunming Qi MD, Dongmei Yan MD, Tingting Qiu MD, Tingyu Hu BD, Weiying Gu MD, Jun Qian MD, Fan Xia MD, Na Qi MD, Congqian Jin BD, Yang Liu MD, Xue Wang MD, Yanlei Zhang MSc, Shuixiu Peng MSc, Prof Zhenyu Li
For patients with multiple myeloma progression after anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, the optimal salvage treatment strategies remain unclear. GPRC5D-directed CAR T cell might be a potential option. The aim of this trial was to investigate the activity and safety of anti-GPRC5D CAR T cells in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy.
-
Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial Lancet Haematol. (IF 15.4) Pub Date : 2025-04-10 Prof Christoph Male MD, Anthonie W A Lensing MD, Prof Anthony K C Chan MD, Prof Gili Kenet MD, Prof Guy Young MD, Rukhmi Bhat MD, Akos F Pap MSc, Dagmar Kubitza MD, Prof Martin H Prins MD, Prof Paul Monagle MD, EINSTEIN-Jr Phase 3 Investigators, Maria Abbattista, Sanjay Ahuja, Manuela Albisetti-Pedroni, Pascal Amedro, Rui Anjos, Ali Antmen, Angela Aramburo, Andrea Artoni, Estela Azeka, Susan Baird
Extended-phase anticoagulation of venous thromboembolism in children is not well documented nor systematically reported. Previously, we reported on recurrent venous thromboembolism and bleeding during acute-phase anticoagulation in EINSTEIN-Jr, a randomised controlled study in 500 children with venous thromboembolism comparing rivaroxaban to standard anticoagulants. The aim of the present study was
-
-
Cold-induced urticaria in multiple myeloma Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 Arjan J Kwakernaak MD PhD, Peter A von dem Borne MD PhD, Josephine M I Vos MD PhD
-
Fedratinib for patients with myelofibrosis Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 Sophie Le Grand, Pierre Guy, Suzanne Tavitian, Magali Colombat, Julie Belliere
-
Fedratinib for patients with myelofibrosis Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 Ruben Van Dijck, John-John Schnog, Peter te Boekhorst
-
Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 Charles J Milrod MD, Lila Rubin MD, Boris Martinez MD, Thomas A Ollila MD, Adam J Olszewski MD, Ari Pelcovits MD
Indolent lymphomas are generally incurable, with protracted disease courses. The approval of drug treatment options often relies on surrogate endpoints (eg, progression-free survival), which do not capture patient-centred outcomes such as quality of life (QOL). This systematic review characterises the use of QOL as an endpoint in randomised controlled trials (RCTs) of indolent lymphomas, and the association
-
-
Rising to the challenge: an international Delphi consensus study on fetal and neonatal alloimmune thrombocytopenia Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 Romy Pothof BSc, Elske M van den Akker-van Marle PhD, Thijs W de Vos MD PhD, Heidi Tiller MD PhD, Prof James B Bussel MD, Maria Therese Ahlén PhD, Brian R Curtis PhD, Prof Enrico Lopriore MD, E J T (Joanne) Verweij MD PhD, Prof Masja de Haas, FNAIT modified Delphi expert group
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a condition in which a fetus is at risk for severe thrombocytopenia, possibly resulting in intracranial haemorrhage, due to maternal alloantibodies formed against human platelet antigens (HPAs). Currently, no FNAIT screening programme exists. Pregnancies at risk of FNAIT are identified in individuals who have previously given birth to a child
-
Improving SARS-CoV-2 vaccine response is challenging in chronic lymphocytic leukaemia Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 Francesca Romana Mauro
-
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 Jonathan A Cook PhD, Piers E M Patten PhD, Nicholas Peckham MSc, Paul Moss PhD, Neil Phillips MBBS, Abhishek Abhishek PhD, Thomas Roberts MSc, Marie Hodges PhD, Georgina Talbot MBChB, Vicki Barber PhD, Anne Francis DPhil, Adrian M Shields PhD, Lelia Duley, Robbert Hoogeboom PhD, Brian J Willett PhD, Sam Scott MSc, Nilima Parry-Jones MD, Toby A Eyre MD, Gareth Plested, Gratian Vandici DPhil, Farooq
Chronic lymphocytic leukaemia is the commonest leukaemia and is associated with profound immunosuppression. Bruton tyrosine kinase inhibitors (BTKi) have revolutionised chronic lymphocytic leukaemia management; however, therapy impairs vaccine-induced immunity. We evaluated whether a 3-week pause of BTKi treatment improved spike protein receptor binding domain (RBD) immunity to SARS-CoV-2 booster vaccination
-
Celebrating 5 years of Women in Lymphoma: a road to equality, diversity, and inclusion in the field Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 Anna Sureda, Astrid Pavlosky, Michelle L Poon, Sonali Smith, Women in Lymphoma Steering Committee
-
Establishment of a haematopoietic cell transplantation programme for children with sickle cell disease in Tanzania Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 Fabio Giglio, Stella Malangahe, Shakilu Jumanne, Melikiard Mhozya, Alphonse Chandika, Cornelio Uderzo
-
CAR T-cell therapy: navigating real-world challenges beyond clinical trials Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 The Lancet Haematology
-
Fedratinib for patients with myelofibrosis – Authors’ reply Lancet Haematol. (IF 15.4) Pub Date : 2025-03-31 Claire N Harrison, Patrick Brown, Jean-Jacques Kiladjian
-
Monumen-TAL progress in the treatment of relapsed multiple myeloma Lancet Haematol. (IF 15.4) Pub Date : 2025-03-13 Susan Bal
-
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study Lancet Haematol. (IF 15.4) Pub Date : 2025-03-13 Prof Hasmukh Jain DM, Atharva Karulkar PhD, Devanshi Kalra MSc, Smrithi Ravikumar MSc, Shreshtha Shah MSc, Afrin Firfiray MSc, Juber Pendhari MPharm, Ankesh Kumar Jaiswal PhD, Aalia Khan MSc, Manivasagam Sundharam MSc, Anand Vaibhaw MSc, Ashish Saroha PhD, Shreewardhan Rajyopadhye PhD, Moumita Basu PhD, Sweety Asija MSc, Ambalika Chowdhury MSc, Rohit Beher MTech, Ankit Banik MSc, Alka Dwivedi PhD,
In low-income and middle-income counties (LMICs), the outcome of relapsed or refractory B-cell malignancies is poor due to the absence of effective therapies. We report the results of a phase 1/2 study of a novel humanised anti-CD19 4-1BB chimeric antigen receptor (CAR) T-cell therapy, talicabtagene autoleucel, for patients with relapsed or refractory B-cell malignancies.
-
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study Lancet Haematol. (IF 15.4) Pub Date : 2025-03-13 Prof Ajai Chari MD, Prof Cyrille Touzeau MD, Carolina Schinke MD, Prof Monique C Minnema MD, Jesus G Berdeja MD, Albert Oriol MD, Prof Niels W C J van de Donk MD, Paula Rodríguez-Otero MD, Daniel Morillo MD, Carmen Martinez-Chamorro MD, María-Victoria Mateos MD, Prof Luciano J Costa MD, Jo Caers MD, Prof Leo Rasche MD, Prof Amrita Krishnan MD, Jing Christine Ye MD, Lionel Karlin MD, Prof Brea Lipe
Talquetamab is the first GPRC5D × CD3 bispecific antibody approved for relapsed or refractory multiple myeloma. In phase 1 of the MonumenTAL-1 study, initial results of subcutaneous talquetamab 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks showed preliminary clinical activity. We describe safety and activity results in patients treated with talquetamab, including patients who had received previous
-
CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India Lancet Haematol. (IF 15.4) Pub Date : 2025-03-13 Luca Paruzzo, Marco Ruella
-
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial Lancet Haematol. (IF 15.4) Pub Date : 2025-03-12 Prof Miguel R Abboud MD, Rodolfo D Cançado PhD, Prof Mariane De Montalembert PhD, Prof Wally R Smith MD, Prof Hala Rimawi FRCP-UK, Ersi Voskaridou MD, Prof Birol Güvenç MD, Prof Kenneth I Ataga MD, Deborah Keefe MD MPH, Kai Grosch PhD, Jimmy Watson MBBS, Evgeniya Reshetnyak PhD, Michele L Nassin MD MS, Yvonne Dei-Adomakoh MD
Crizanlizumab has previously shown efficacy as a potent disease-modifying therapy for alleviating vaso-occlusive crisis in sickle cell disease. The SUSTAIN study showed a reduction of vaso-occlusive crises in patients treated with 5 mg/kg crizanlizumab, compared with placebo. The STAND study aimed to evaluate the efficacy and safety of two doses (5·0 mg/kg and 7·5 mg/kg) of crizanlizumab in sickle
-
Now where do we STAND with crizanlizumab? Lancet Haematol. (IF 15.4) Pub Date : 2025-03-12 Sebastian Mendez-Marti, Swee Lay Thein
-
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study Lancet Haematol. (IF 15.4) Pub Date : 2025-03-05 Luis Malpica MD, Henry Idrobo MD, Astrid Pavlovsky MD, Prof Eliana C M Miranda PhD, Denisse Castro MD, Prof Brady Beltran MD, Daniel J Enriquez MD, Jule F Vasquez MD, Claudia Roche MD, Fabiola Valvert MD, Prof Luis Villela MD, Thais Fischer MD, Juliana Pereira MD, Renata L R Baptista MD, Guilherme Duffles MD, Sergio A B Brasil MD, Carolina Oliver MD, Jamila Vaz Tavarez MD, Fernando Warley MD, Lorena
Peripheral T-cell lymphomas represent a rare and heterogeneous group of mature T-cell neoplasms characterised by aggressive behavior. Previous studies evaluating peripheral T-cell lymphoma epidemiology across Latin America have been restricted in their representation of most countries in the region. In this study, we aimed to describe peripheral T-cell lymphoma epidemiology across Latin America.
-
Peripheral T-cell lymphoma in the Latin American population Lancet Haematol. (IF 15.4) Pub Date : 2025-03-05 Eva Domingo Domenech
-
-
Epistemic limitations of measurable residual disease in haematological malignancies. Lancet Haematol. (IF 15.4) Pub Date : 2025-03-01 Benjamin Chin-Yee,Lucie Laplane,Pierre Sujobert
The growing use of measurable residual disease (MRD) assays across haematology-oncology creates an urgent need for clinicians and researchers to reflect on the biological and clinical rationale of this class of biomarkers. In this Viewpoint, we critically examine two premises behind MRD's use in haematology-oncology, focusing on its biological plausibility as a predictive biomarker and surrogate endpoint
-
Reproductive justice and sickle cell disease: a call for a whole-person approach to care. Lancet Haematol. (IF 15.4) Pub Date : 2025-03-01 Maayan Leroy-Melamed,Teonna Wolford,Sona Smith,Victoria Adewale,Maya Bloomberg,Allison McGirr-Crowley,Patrick T McGann
-
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe. Lancet Haematol. (IF 15.4) Pub Date : 2025-03-01 Hélène Schoemans,Elke Stienissen,Kathy Goris,Susan K Stewart,Meredith Cowden,Kristina Arnahoutova,Steven Z Pavletic,Hildegard Greinix,Anna Barata,Lorna Warwick,Natacha Bolanos,Isabel Barbosa,Guy Bouguet,Isabelle Lhenry-Yvon,Riikka-Leena Manninen,Simona Pavukova,Guy Tavori,Marleen van Amerongen,Anita Lawitschka,Kirk R Schultz,Daniel Wolff,Anne Herrmann
Graft-versus-host disease (GVHD) is a complication of hematopoietic cell transplantation (HCT) that has a low chance of complete remission and a substantial effect on morbidity and mortality. To better understand how to improve the field of GVHD research, management, and care, the cGVHD Eurograft Initiative organised a European community advisory board of patient advocates, with the assistance of the
-
Global paediatric haematopoietic stem-cell transplantation training and access: providing strategies to overcome challenges. Lancet Haematol. (IF 15.4) Pub Date : 2025-03-01 Candice Laverne Hendricks,Manuela Spadea,Justin Rudolph Du Toit,Carmelo Gurnari,Rafaella Muratori,Valentine Jimenez,Vera Radici,Sheila Torrado,Nihar Desai,Azada Ibrahimova,Ibrahim N Muhsen,Julio Ropero,Nico Gagelmann,Claire Horgan
-
Do we need another TKI for chronic myeloid leukaemia? Lancet Haematol. (IF 15.4) Pub Date : 2025-03-01 Henrik Hjorth-Hansen
-
Long-term neurodevelopmental outcomes in infants with haemolytic disease of the newborn treated with darbepoetin. Lancet Haematol. (IF 15.4) Pub Date : 2025-03-01 Derek P de Winter,Isabelle M C Ree,Masja de Haas,E J T Joanne Verweij,Enrico Lopriore,Jeanine M M van Klink
-
Multisystem lymphomatoid granulomatosis in an immunocompetent woman. Lancet Haematol. (IF 15.4) Pub Date : 2025-03-01 Laura Nayeli Tecayehuatl-Negrete,Ana Lilia Peralta-Amaro,Karla Alejandra Romero-Cuevas,José Emmanuel Zúñiga-Espinosa,Roberto Alfredo Ibarra-Ponce de León
-
-
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial Lancet Haematol. (IF 15.4) Pub Date : 2025-02-10 Prof Maria Domenica Cappellini MD, Prof Vip Viprakasit MD, Pencho Georgiev MD, Thomas D Coates MD, Prof Raffaella Origa PhD, Abderrahim Khelif MD, Hong-Keng Liew MBBS, Adisak Tantiworawit MD, Lee-Ping Chew MD, Abdalla Khalil MD, Prof P Joy Ho MBBS, Kevin H M Kuo MD, Natalia Holot MD, Martina Perin PhD, Ana Carolina Giuseppi MD, Wen-Ling Kuo PhD, Yinzhi Lai PhD, Loyse Felber Medlin PhD, Luciana Moro
Treatments to reduce red blood cell (RBC) transfusion burden among patients with transfusion-dependent β-thalassaemia remain limited. Here, we report long-term follow-up data from the phase 3 BELIEVE trial of luspatercept for transfusion-dependent β-thalassaemia.
-
What we now BELIEVE is achievable with luspatercept in transfusion-dependent β-thalassaemia Lancet Haematol. (IF 15.4) Pub Date : 2025-02-10 Khaled M Musallam
-
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial Lancet Haematol. (IF 15.4) Pub Date : 2025-02-07 Jorge E Cortes MD, Prof Dong-Wook Kim MD PhD, Tapan Saikia MD, Navin Khattry MD, Krishnakumar Rathnam MD, Yesid Alvarado MD, Guy Hannah MD, Srinivas K Tantravahi MD, Prof Jane F Apperley MD, Aude Charbonnier MD PhD, Prof Valentin García-Gutiérrez MD, Alessandro Lucchesi MD PhD, Delia Dima MD, Prof Árpád Illés PhD, Viola M Popov MD PhD, Prof Elisabetta Abruzzese MD, Arijit Nag MBBS, Shashikant Apte
Resistance or intolerance to the available tyrosine kinase inhibitors (TKIs) remains a treatment challenge for patients with chronic myeloid leukaemia. We aimed to report the safety, antileukaemic activity, and pharmacokinetics of oral vodobatinib, a novel selective BCR::ABL1 TKI, in patients with Philadelphia chromosome-positive (Ph-positive) chronic myeloid leukaemia who previously received at least
-
Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial Lancet Haematol. (IF 15.4) Pub Date : 2025-02-04 Prof Sijian Yu MD, Fen Huang MD, Na Xu MD, Zhongming Zhang MD, Can Liu MD, Xiaojun Xu MD, Zhiping Fan MD, Xiangzong Zeng MD, Qiong Liu MS, Guo Qiu MS, Prof Xu Xi MD, Ren Lin MD, Xinquan Liang MD, Yirong Jiang MD, Prof Min Dai MD, Hua Jin MD, Xiaofang Li MD, Prof Shunqing Wang MD, Meiqing Wu MD, Prof Jing Sun MD, Prof Li Xuan MD, Prof Qifa Liu MD
Retrospective studies suggested that haploidentical transplantation combined with unrelated cord blood might improve survival for patients with haematological malignancies. We aimed to assess whether transplantation of haploidentical peripheral blood stem cells (PBSCs) plus unrelated cord blood would achieve superior disease-free survival compared with transplantation of haploidentical PBSCs plus bone
-
Fine-tuning of haploidentical haematopoietic stem cell transplantation Lancet Haematol. (IF 15.4) Pub Date : 2025-02-04 Yoshinobu Kanda
-
2024 ASH Annual Meeting Lancet Haematol. (IF 15.4) Pub Date : 2025-02-03 Daniela Marín, Lan-Lan Smith
-
Cristóbal Frutos: confronting treatment barriers Lancet Haematol. (IF 15.4) Pub Date : 2025-02-03 Ray Cavanaugh
-
-
Pioneering a new field of computational pharmacophenomics to unlock the life-saving potential of existing medicines Lancet Haematol. (IF 15.4) Pub Date : 2025-02-03 David C Fajgenbaum, Sally Nijim, Grant Mitchell, Matej Macak, Chris Bizon, Alexander Tropsha, David Koslicki
-
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study Lancet Haematol. (IF 15.4) Pub Date : 2025-02-03 Pasquale Niscola
-
Optimising quadruplet regimens to broaden eligibility in multiple myeloma Lancet Haematol. (IF 15.4) Pub Date : 2025-02-03 Tanya M Wildes
-
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study Lancet Haematol. (IF 15.4) Pub Date : 2025-02-03 Hege Kristin Gravdahl Garelius PhD, Timothy Bagguley MSc, Adele Taylor PhD, Pierre Fenaux MD PhD, David Bowen MD PhD, Argiris Symeonidis MD PhD, Moshe Mittelmann MD, Reinhard Stauder MD MSc, Jaroslav Čermák MD PhD, Guillermo Sanz MD PhD, Saskia Langemeijer MD PhD, Luca Malcovati MD PhD, Ulrich Germing MD PhD, Laurence Sanhes MD, Maud d'Aveni MD PhD, Dominic Culligan MD, Ioannis Kotsianidis MD PhD,
In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodysplastic syndromes from the European MDS (EUMDS) Registry, we showed that patients treated with ESAs had longer survival compared with patients who receive red blood cell transfusion (RBCT). In this study, with a longer follow up time and more patients included, we aimed to assess long-term effects on survival
-
Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet Lancet Haematol. (IF 15.4) Pub Date : 2025-02-03 Vincent Ribrag MD, Prof Dominique Bron MD PhD, Grzegorz Rymkiewicz MD PhD, Prof Dieter Hoelzer MD PhD, Judit Jørgensen MD, Aythami de Armas-Castellano BS, Maria Trujillo-Martín PhD, Prof Pierre Fenaux MD PhD, Prof Luca Malcovati MD PhD, Natacha Bolaños, Prof Josep-Maria Ribera MD PhD, Prof Charles Herbaux MD PhD, Clémentine Sarkozy MD PhD, Prof Pier Luigi Zinzani MD PhD, Prof Jan Walewski MD PhD, Prof
Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas. Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains an area of clinical and biological research with specificities due to the high incidence of CNS involvement and tumour lysis syndrome in patients with a high tumour burden. Few consensus recommendations are available concerning
-
Inclusion matters: progress in haematological trials for pregnant individuals Lancet Haematol. (IF 15.4) Pub Date : 2025-02-03 The Lancet Haematology
-
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial Lancet Haematol. (IF 15.4) Pub Date : 2025-02-03 Frida Bugge Askeland MD, Einar Haukås MD, Tobias S Slørdahl MD, Anja Klostergaard MD, Tatjana Alexandersen MPH, Liv Osnes MD, Anna Lysén PhD, Pegah Abdollahi PhD, Lene Kongsgaard Nielsen MD, Emil Hermansen MD, Fredrik Schjesvold MD
Adding anti-CD38 monoclonal antibodies to standard therapies can improve outcomes in patients with multiple myeloma. Long-term treatment with corticosteroids increases the risk of infection. We aimed to evaluate the safety and activity of isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone in patients with newly diagnosed multiple myeloma ineligible for autologous haematopoietic
-
Low-dose aspirin versus placebo in postpartum venous thromboembolism: a multi-national, pilot, randomised, placebo-controlled trial Lancet Haematol. (IF 15.4) Pub Date : 2025-01-16 Leslie Skeith MD, A Kinga Malinowski MD, Darine El-Chaâr MD, Wee-Shian Chan MD, Jennifer Donnelly MD, Céline Chauleur PhD, Wessel Ganzevoort PhD, Stephen Wood MD, Suzanne Dubois BA, Claire McCarthy MD, Andrea Buchmuller MD, Hanke Wiegers PhD, Paul S Gibson MD, Fionnuala Ní Áinle PhD, Saskia Middeldorp PhD, Lisa Duffett MD, Shannon M Bates MDCM, Alexandra Garven BScKin, Jill Baxter BScKin, Brendan Cord
Despite the morbidity and mortality of venous thromboembolism, there is little evidence to guide postpartum thromboprophylaxis in patients at moderate risk. We aimed to assess the feasibility of conducting a double-blind, randomised trial of aspirin versus placebo in postpartum individuals with two or more venous thromboembolism risk factors, mild-to-moderate thrombophilia, or both.
-
Is it time for a large trial to evaluate aspirin for obstetric venous thromboembolism prophylaxis? Lancet Haematol. (IF 15.4) Pub Date : 2025-01-16 Alexander M Friedman
-
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study Lancet Haematol. (IF 15.4) Pub Date : 2025-01-09 Xin Zhao MD, Prof Jing Sun MD, Prof Zhihua Zhang MD, Miao Chen MD, Tiejun Gong MD, Guangsheng He MD, Yingmei Li MD, Prof Hong Liu MD, Prof Fei Li MD, Xin Li MD, Prof Hu Zhou MD, Xiaoqin Wang MD, Prof Mei Hong MD, Lei Lei MD, Hongyan Yin MD, Xian Luo MSc, Yang Li MS, Songhua Fan MD, Xiaojun Guo MD, Michael M Shi MD, Weiguo Su PhD, Prof Liansheng Zhang MD, Prof Bing Han MD, Prof Fengkui Zhang MD
Spleen tyrosine kinase inhibitors are potential treatment options for warm autoimmune haemolytic anaemia. This study aimed to assess the preliminary efficacy and safety of sovleplenib—an oral spleen tyrosine kinase inhibitor—in patients with warm autoimmune haemolytic anaemia in China. Here we report on the phase 2 results.
-
Expanding treatment options for warm autoimmune haemolytic anaemia Lancet Haematol. (IF 15.4) Pub Date : 2025-01-09 Sigbjørn Berentsen
-
Haematology and climate change Lancet Haematol. (IF 15.4) Pub Date : 2025-01-03 The Lancet Haematology
-
Position statement on the diagnosis and management of acute leukaemia and aggressive lymphomas in pregnancy Lancet Haematol. (IF 15.4) Pub Date : 2025-01-03 Georgia Mills MBBS, Antonia Shand MMed, Debra Kennedy MBBS, Sandra Lowe MD, Victoria Bilsland MMktg, Briony Cutts MD, Bruce McBride MSc, Wendy Brown MPH, Srinivas Bolisetty MD, Eva A Wegner MHM, Giselle Kidson-Gerber MBBS
Haematological malignancies affect 12·5 in 100 000 pregnancies. Over the past two decades, the number of haematological malignancies in pregnancy has substantially increased. Life-threatening haematological malignancies in pregnancy, such as acute leukaemia and aggressive lymphomas, pose a unique therapeutic challenge: clinicians must consider both maternal and fetal wellbeing, aiming to deliver optimal
-
Re-energising therapy options in sickle cell disease: the mitapivat phase 2 trial results Lancet Haematol. (IF 15.4) Pub Date : 2025-01-03 Parul Rai, Jane S Hankins
-
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial Lancet Haematol. (IF 15.4) Pub Date : 2025-01-03 Roberto Mina MD, Anne K Mylin MD, Hisayuki Yokoyama MD, Hila Magen MD, Winfried Alsdorf MD, Monique C Minnema MD, Leyla Shune MD, Iris Isufi MD, Simon J Harrison PhD, Urvi A Shah MD, Jordan M Schecter MD, Martin Vogel MD, Nikoletta Lendvai MD, Katharine S Gries PhD, Eva G Katz PhD, Ana Slaughter PhD, Carolina Lonardi PharmD, Jane Gilbert MSc, Quanlin Li MS, William Deraedt MSc, Octavio Costa Filho
In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory multiple myeloma. We report here patient-reported outcomes.
-
Patient reported outcomes with earlier use of chimeric antigen receptor-T cell therapy in multiple myeloma Lancet Haematol. (IF 15.4) Pub Date : 2025-01-03 Alissa Visram, Hira Mian
-
The challenges of detecting early efficacy signals in lymphoma trials Lancet Haematol. (IF 15.4) Pub Date : 2025-01-03 Eva Hoster, Christian Schmidt